Isatuximab is produced and developed by which company?

Isatuximab is a monoclonal antibody drug targeting CD38 and is mainly used to treat patients with relapsed or refractory multiple myeloma. The drug binds to the CD38 antigen, activates the immune cell killing mechanism, and induces tumor cell apoptosis, thereby inhibiting myeloma cell proliferation. Clinically, isatuximab is often used in combination with other anti-myeloma drugs to enhance efficacy and improve patient prognosis.

The research and development of isatuximab is led by the French company Sanofi (Sanofi), whose R&D team has accumulated rich experience in the fields of antibody engineering and immuno-oncology. Through years of clinical trials and drug optimization, Sanofi has verified the efficacy, safety and applicable populations of isatuximab, laying a solid foundation for its launch and promotion. The original drugs comply with international drug regulatory standards in terms of quality control, purity and stability.

In terms of production, isatuximab adopts modern biopharmaceutical technology, through recombinant cell culture, high-purity purification and strict quality testing to ensure the consistency of the ingredients and activity of each batch of drugs. This production process not only ensures the stability and reliability of the drug in clinical use, but also provides guarantee for large-scale supply. Sanofi has established a unified production and quality management system globally to meet the clinical needs of different countries and regions.

Isatuximab's international production and research and development background ensures reliable efficacy and safety in clinical applications. Domestic patients can obtain the drug through large hospitals and regular pharmacies, and must follow the doctor's prescription and medication regimen. After the drug is launched, Sanofi also provides relevant clinical support and patient education services to help doctors and patients better understand medication specifications, efficacy evaluation and adverse reaction management. Overall, the development and production of isatuximab are based on a mature international biopharmaceutical platform, providing a safe and reliable treatment option for multiple myeloma patients.

Reference materials:https://en.wikipedia.org/wiki/Isatuximab